开发KCC2疗法来治疗神经系统疾病
Shilpa D Kadam1, Shane V Hegarty1
1Axonis Therapeutics Inc., Boston, MA, United States.
Frontiers in molecular neuroscience
|December 25, 2024
概括
低功能的KCC2 (化物共载体2) 损害了神经元的抑制,导致神经系统疾病. 恢复KCC2功能为这些疾病提供了一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- KCC2 (化物共运输体2) 对于中枢神经系统神经元中的化物梯度至关重要,使突触抑制成为可能.
- KCC2低功率与神经系统疾病有关,这些神经系统疾病的特征是刺激/抑制 (E/I) 不平衡.
研究的目的:
- 突出KCC2缺陷功能作为各种神经系统疾病中的中心病理.
- 讨论针对KCC2恢复神经元抑制的治疗潜力.
主要方法:
- 对KCC2功能,病理学和治疗策略的现有文献的审查.
- 对KCC2上调调的治疗方法的临床前数据的分析.
主要成果:
- KCC2低功率导致GABAergic/glycinergic抑制受损,导致神经元过度兴奋和神经功能受损.
- KCC2是,智力障碍,自闭症谱系障碍和精神疾病的基因验证标.
- 在临床前研究中,KCC2上调显示出增强抗发作和止痛功效的前临床研究有希望.
结论:
- KCC2低功率是E/I不平衡障碍背后的一种保存机制.
- 开发KCC2增强疗法为恢复中枢神经系统抑制和克服药物耐药性提供了一种新的方法.
更多相关视频
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.5K
11:51Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
30.3K
相关概念视频
01:28Preclinical Development: Overview
4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K
01:46Electron Transport Chain: Complex I and II
9.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.5K